Citation Impact
Citing Papers
Unique carbohydrate–carbohydrate interactions are required for high affinity binding between FcγRIII and antibodies lacking core fucose
2011
Emerging Principles for the Therapeutic Exploitation of Glycosylation
2014 Science
Deciphering O -glycoprotease substrate preferences with O-Pair Search
2022 StandoutNobel
Computational design of soluble and functional membrane protein analogues
2024 StandoutNatureNobel
Glycoproteomic Analysis of Antibodies
2013
Improved Virus Neutralization by Plant-produced Anti-HIV Antibodies with a Homogeneous β1,4-Galactosylated N-Glycan Profile
2009
Dynamics of Inter-heavy Chain Interactions in Human Immunoglobulin G (IgG) Subclasses Studied by Kinetic Fab Arm Exchange
2014
Evaluation of the serum N ‐linked glycome for the diagnosis of cancer and chronic inflammation
2008
N-glycans as functional effectors of genetic and epigenetic disease risk
2020
Global view of human protein glycosylation pathways and functions
2020
Treatment Response in Kawasaki Disease Is Associated with Sialylation Levels of Endogenous but Not Therapeutic Intravenous Immunoglobulin G
2013
Fc Glycan-Modulated Immunoglobulin G Effector Functions
2014
Crystal structure of the human IgG4 CH3 dimer reveals the role of Arg409 in the mechanism of Fab-arm exchange
2012
Rheumatoid arthritis
2018 Standout
Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action
2009
Rheumatoid arthritis
2016 Standout
Structural characterization of the maytansinoid–monoclonal antibody immunoconjugate, huN901–DM1, by mass spectrometry
2005
Chemoenzymatic Fc Glycosylation via Engineered Aldehyde Tags
2014 StandoutNobel
Site‐Specific and Stoichiometric Modification of Antibodies by Bacterial Transglutaminase
2010
Bypassing glycosylation: engineering aglycosylated full-length IgG antibodies for human therapy
2011
Chronic Inflammation (Inflammaging) and Its Potential Contribution to Age-Associated Diseases
2014 Standout
Inflammaging: a new immune–metabolic viewpoint for age-related diseases
2018 Standout
Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor
2006
Glycosylation engineering of therapeutic IgG antibodies: challenges for the safety, functionality and efficacy
2017
Structural Comparison of Fucosylated and Nonfucosylated Fc Fragments of Human Immunoglobulin G1
2007
Establishment of FUT8 knockout Chinese hamster ovary cells: An ideal host cell line for producing completely defucosylated antibodies with enhanced antibody‐dependent cellular cytotoxicity
2004
Fcγ receptors as regulators of immune responses
2007 Standout
Structural Characterization of Anti-Inflammatory Immunoglobulin G Fc Proteins
2014
Biological roles of glycans
2016 Standout
Inflammation and tumor progression: signaling pathways and targeted intervention
2021 Standout
Glycosylation as a strategy to improve antibody-based therapeutics
2009
Targeting apoptosis in cancer therapy
2020 Standout
Selection of a human anti-RhD monoclonal antibody for therapeutic use: Impact of IgG glycosylation on activating and inhibitory FcγR functions
2005
Terminal sugars of Fc glycans influence antibody effector functions of IgGs
2008
Human antibody–Fc receptor interactions illuminated by crystal structures
2004
The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans
2021 StandoutNobel
Glycotherapy: New Advances Inspire a Reemergence of Glycans in Medicine
2013 StandoutNobel
Challenges of glycosylation analysis and control: an integrated approach to producing optimal and consistent therapeutic drugs
2016
Sweet and Sour: The Role of Glycosylation for the Anti-inflammatory Activity of Immunoglobulin G
2014
Defining roles of specific reactive oxygen species (ROS) in cell biology and physiology
2022 Standout
The role of biosimilars in the treatment of rheumatic diseases
2012
Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality
2006
Advances in plant molecular farming
2010
IgG4-related disease
2014 Standout
Restricted Motion of the Conserved Immunoglobulin G1 N-Glycan Is Essential for Efficient FcγRIIIa Binding
2014
Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life
2019
A close look at human IgG sialylation and subclass distribution after lectin fractionation
2009
A Pragmatic Guide to Enrichment Strategies for Mass Spectrometry–Based Glycoproteomics
2020 StandoutNobel
Development of therapeutic antibodies for the treatment of diseases
2020 Standout
Anti-citrullinated protein antibodies acquire a pro-inflammatory Fc glycosylation phenotype prior to the onset of rheumatoid arthritis
2013
Discovery and resupply of pharmacologically active plant-derived natural products: A review
2015 Standout
Isotype and glycoform selection for antibody therapeutics
2012
Glycosylation in cancer: mechanisms and clinical implications
2015 Standout
Generation and Comparative Characterization of Glycosylated and Aglycosylated Human IgG1 Antibodies
2012
Antibody Glycosylation and Its Impact on the Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies and Fc-Fusion Proteins
2015
IgG Subclasses and Allotypes: From Structure to Effector Functions
2014 Standout
A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface
2016
Fc-Glycosylation of IgG1 is Modulated by B-cell Stimuli
2011
Fucose Depletion from Human IgG1 Oligosaccharide Enhances Binding Enthalpy and Association Rate Between IgG1 and FcγRIIIa
2004
Glycoproteomics
2022 StandoutNobel
Crystal Structure of a Homogeneous IgG-Fc Glycoform with the N-Glycan Designed to Maximize the Antibody Dependent Cellular Cytotoxicity
2017
Identification of a receptor required for the anti-inflammatory activity of IVIG
2008
Species-Specific Determinants in the IgG CH3 Domain Enable Fab-Arm Exchange by Affecting the Noncovalent CH3–CH3 Interaction Strength
2011
Glycoengineering of Human IgG1-Fc through Combined Yeast Expression and in Vitro Chemoenzymatic Glycosylation
2008
Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies
2006
The Impact of Glycosylation on the Biological Function and Structure of Human Immunoglobulins
2006
Glycoengineered antibodies: towards the next-generation of immunotherapeutics
2018
Chemoenzymatic Synthesis and Fcγ Receptor Binding of Homogeneous Glycoforms of Antibody Fc Domain. Presence of a Bisecting Sugar Moiety Enhances the Affinity of Fc to FcγIIIa Receptor
2011
Chemoenzymatic Glycoengineering of Intact IgG Antibodies for Gain of Functions
2012
Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells
2008
Structural Basis for FcγRIIa Recognition of Human IgG and Formation of Inflammatory Signaling Complexes
2011
Precision glycocalyx editing as a strategy for cancer immunotherapy
2016 StandoutNobel
General mechanism for modulating immunoglobulin effector function
2013
Formylglycine, a Post-Translationally Generated Residue with Unique Catalytic Capabilities and Biotechnology Applications
2014 StandoutNobel
N-glycomic biomarkers of biological aging and longevity: A link with inflammaging
2012
Chemical and Structural Analysis of an Antibody Folding Intermediate Trapped during Glycan Biosynthesis
2012
Site-Specific Antibody–Drug Conjugates: The Nexus of Bioorthogonal Chemistry, Protein Engineering, and Drug Development
2014 StandoutNobel
Mass spectrometry analysis of in vitro nitration of a recombinant human IgG1 monoclonal antibody
2007
State of the scientific knowledge on properties and genesis of Anthropogenic Dark Earths in Central Amazonia (terra preta de Índio)
2012 Standout
Agalactosylated IgG antibodies depend on cellular Fc receptors forin vivoactivity
2007
Computational design of a pH-sensitive IgG binding protein
2013 StandoutNobel
Works of S. Krapp being referenced
Structural Analysis of Human IgG-Fc Glycoforms Reveals a Correlation Between Glycosylation and Structural Integrity
2003 Nobel